<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="150702">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01138332</url>
  </required_header>
  <id_info>
    <org_study_id>AAML10B10</org_study_id>
    <secondary_id>COG-AAML10B10</secondary_id>
    <secondary_id>CDR0000671489</secondary_id>
    <secondary_id>NCI-2011-02226</secondary_id>
    <nct_id>NCT01138332</nct_id>
  </id_info>
  <brief_title>Biomarkers in Young Patients With Acute Myeloid Leukemia</brief_title>
  <official_title>Stat3 Signaling Pathway Aberrancies in Pediatric AML</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Oncology Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help
      doctors learn more about biomarkers related to cancer.

      PURPOSE: This research study is studying biomarkers in tissue samples from young patients
      with acute myeloid leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the frequency of ligand-independent phosphorylation of Stat3 in a small
           cohort of samples from pediatric patients with acute myeloid leukemia including, but
           not limited to, samples known to express mutated c-kit.

        -  Measure the level of Stat3 phosphorylation in these samples after stimulation of three
           key cytokine receptors expressed on hematopoietic cells IL-6R, G-CSFR, and c-kit.

      OUTLINE: Cryopreserved samples are analyzed for levels of various components of the Stat3
      pathway via western blotting.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Correlations between levels of pY-Stat3 and levels of upstream cytokine receptors</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Association of constitutive and/or increased pY-Stat3 and c-kit genotype</measure>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">20</enrollment>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>western blotting</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Diagnosis of acute myeloid leukemia
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of acute myeloid leukemia

          -  One of the following karyotypes:

               -  t(8;21) and WT c-kit

               -  t(8;21) and mutant c-kit

               -  Normal karyotype

        PATIENT CHARACTERISTICS:

          -  Not specified

        PRIOR CONCURRENT THERAPY:

          -  Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michele S. Redell, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Texas Children's Cancer Center</affiliation>
  </overall_official>
  <verification_date>May 2015</verification_date>
  <lastchanged_date>May 5, 2015</lastchanged_date>
  <firstreceived_date>June 4, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>childhood acute myeloid leukemia/other myeloid malignancies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
